In vivo tumor co-transfection with superantigen and CD80 induces systemic immunity without tolerance and prolongs survival in mice with hepatocellular carcinoma.

摘要: Background: Since transfection of established tumors with immunostimulatory genes can elicit antitumor immunity, we treat mouse HCC in vivo superantigen SEA and/or costimulatory molecule CD80 and evaluated the safety efficacy. Methods Mice were treated lipid-complexed plasmid DNA encoding staphylococcal enterotoxin A CD80. Then mice for tumor regression, systemic immunologic responses, survival times treatment-associated toxicity. Results Of all mice, overall response rates (complete or partial remission) SEA, SEA/CD80 this study 65%, 60% 75% separately, significantly higher than that untreated mice. Most completed therapy without any significant reaction. CTL activity increased time treatment correlated temporally an objective response. Also our results indicated local intratumoral expression did not lead to detectable ...